JP2022505022A5 - - Google Patents

Info

Publication number
JP2022505022A5
JP2022505022A5 JP2021518633A JP2021518633A JP2022505022A5 JP 2022505022 A5 JP2022505022 A5 JP 2022505022A5 JP 2021518633 A JP2021518633 A JP 2021518633A JP 2021518633 A JP2021518633 A JP 2021518633A JP 2022505022 A5 JP2022505022 A5 JP 2022505022A5
Authority
JP
Japan
Prior art keywords
substance
pharmaceutical
alpha
substance used
emitting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059331 external-priority patent/WO2020089819A1/en
Publication of JP2022505022A publication Critical patent/JP2022505022A/ja
Publication of JP2022505022A5 publication Critical patent/JP2022505022A5/ja
Priority to JP2024174991A priority Critical patent/JP2025013822A/ja
Pending legal-status Critical Current

Links

JP2021518633A 2018-11-01 2019-10-31 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化 Pending JP2022505022A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174991A JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753930P 2018-11-01 2018-11-01
US62/753,930 2018-11-01
PCT/IB2019/059331 WO2020089819A1 (en) 2018-11-01 2019-10-31 Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174991A Division JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Publications (2)

Publication Number Publication Date
JP2022505022A JP2022505022A (ja) 2022-01-14
JP2022505022A5 true JP2022505022A5 (cg-RX-API-DMAC7.html) 2022-10-19

Family

ID=70464034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518633A Pending JP2022505022A (ja) 2018-11-01 2019-10-31 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化
JP2024174991A Pending JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174991A Pending JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Country Status (13)

Country Link
US (2) US12594291B2 (cg-RX-API-DMAC7.html)
EP (2) EP3873598B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022505022A (cg-RX-API-DMAC7.html)
KR (1) KR20210087949A (cg-RX-API-DMAC7.html)
CN (2) CN117338800A (cg-RX-API-DMAC7.html)
AU (3) AU2019370892B2 (cg-RX-API-DMAC7.html)
CA (1) CA3114299A1 (cg-RX-API-DMAC7.html)
ES (1) ES3035872T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250846T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072799T2 (cg-RX-API-DMAC7.html)
PL (1) PL3873598T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202102627PA (cg-RX-API-DMAC7.html)
WO (1) WO2020089819A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350431B2 (en) 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
CN116171152A (zh) * 2020-09-15 2023-05-26 昂科因凡特公司 制备的镭-224和子代联合dna修复抑制剂,用于放射性核素治疗
IL303002B1 (en) 2020-12-16 2026-08-01 Alpha Tau Medical Ltd Radiation therapy using scattered alpha emitters with enhanced beta therapy
CN113230400A (zh) * 2021-03-11 2021-08-10 上海交通大学 一种基于表观遗传调控的金纳米团簇放疗增敏组装体及其制备和应用
CA3211766A1 (en) 2021-03-19 2022-09-22 Gt Medical Technologies, Inc. Custom brachytherapy carriers
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US20220395701A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
US20220395703A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
JP2024521529A (ja) * 2021-06-20 2024-05-31 アルファ タウ メディカル リミテッド 免疫チェックポイント調節因子と組み合わせた腫瘍内アルファ放射体照射
EP4359071A4 (en) * 2021-06-20 2026-04-22 Alpha Tau Medical Ltd Intratumoral Alpha Emitter Radiation in Combination with Vascular System Inhibitors
US12053644B2 (en) 2021-12-30 2024-08-06 Gt Medical Technologies, Inc. Radiation shielding apparatus for implantable radioactive seeds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006243A2 (en) 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
CA2398678A1 (en) 2000-01-31 2001-08-09 Yissum Research Development Company Of The Hebrew University In Jerusalem Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
US20030153083A1 (en) 2000-01-31 2003-08-14 Alexei Shir Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkr
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU7548901A (en) * 2000-06-16 2002-01-02 Sloan Kettering Inst Cancer Liposomal encapsulation of chelated actinium-225 and uses thereof
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
WO2004045491A2 (en) 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
ATE424221T1 (de) 2003-04-30 2009-03-15 Univ Ramot Verfahren und vorrichtung für strahlentherapie
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
US7834064B2 (en) 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
HUE037796T2 (hu) 2005-07-26 2018-09-28 Aplha Tau Medical Ltd Radioaktív felületi forrás és eljárás elõállítására
CN101091794A (zh) * 2006-06-19 2007-12-26 博尔诚(北京)科技有限公司 用于预防和治疗转移性肿瘤的组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090088401A1 (en) 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
US20110038888A1 (en) 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
US20090234628A1 (en) * 2008-03-14 2009-09-17 Siemens Medical Solutions Usa, Inc. Prediction of complete response given treatment data
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
US8821364B2 (en) 2008-09-02 2014-09-02 Battelle Memorial Institute Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue
PT3098239T (pt) 2008-12-22 2020-01-15 Targimmune Therapeutics Ag Vetor de rna de cadeia dupla dirigido ao egfr para o tratamento sistémico de cancro
US9642817B2 (en) 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
WO2011046934A1 (en) * 2009-10-12 2011-04-21 Au Jessie L-S Methods and compositions for improved delivery, expression or activity of rna interference agents
EP2525835A4 (en) * 2010-01-18 2016-01-20 Univ Texas METHOD AND COMPOSITION FOR PARTICLE-CONTROLLED MEDICAMENTAL OUTPUT IN CANCER CELLS
TR201807294T4 (tr) * 2010-06-22 2018-06-21 Centre Nat Rech Scient Nükleik asit konjugatları için endosomolitik ajanlar ile optimize edilmiş in vivo aktarım sistemi.
CN104411331B (zh) 2012-01-13 2018-08-21 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180214583A1 (en) * 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
CN105031648A (zh) * 2015-08-25 2015-11-11 徐州医学院 新型靶向纳米粒子及其制备方法和用途
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
WO2017173101A1 (en) * 2016-03-30 2017-10-05 Virginia Commonwealth University Combination therapy for neuroblastoma using mda-7/il-24 with therapeutic agents
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CN110418651A (zh) * 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018042411A1 (en) 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
EP3321362A1 (en) * 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
WO2018183885A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
MX2019011945A (es) * 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.
SG11201910176PA (en) 2017-05-11 2019-11-28 Alpha Tau Medical Ltd Polymer coatings for brachytherapy devices
JP2020520368A (ja) 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ.エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
EP3688008A1 (en) 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
WO2019173456A1 (en) * 2018-03-06 2019-09-12 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
WO2019170890A1 (en) 2018-03-08 2019-09-12 Targimmune Therapeutics Ag A recombinant protein comprising a double stranded rna binding domain
CN116585625A (zh) 2018-03-08 2023-08-15 阿尔法陶医疗有限公司 放射治疗籽源和施药器
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3856256A1 (en) * 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
SG11202109274TA (en) 2019-04-03 2021-10-28 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
MX2022002753A (es) 2019-10-10 2022-04-06 Alpha Tau Medical Ltd Preparacion humeda de fuentes de radioterapia.

Similar Documents

Publication Publication Date Title
Koka et al. Technological advancements in external beam radiation therapy (EBRT): An indispensable tool for cancer treatment
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
Bert et al. Particle therapy for noncancer diseases
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
JP2018502120A5 (cg-RX-API-DMAC7.html)
Srinivasan et al. A comprehensive overview of radiation therapy impacts of various cancer treatments and pivotal role in the immune system
JP2017515847A5 (cg-RX-API-DMAC7.html)
JP2020501589A5 (cg-RX-API-DMAC7.html)
JP2013523659A5 (cg-RX-API-DMAC7.html)
Dogan et al. Automatic feathering of split fields for step-and-shoot intensity modulated radiation therapy
US7963902B2 (en) Computer prescribed treatment to reduced damage from radiation therapy and chemotherapy
WO2018126280A1 (en) Reducing damage from chemotherapy and increasing cancer kill rates by using interweaved low dose radiation
Wittych et al. Angiosarcoma of the scalp: a case report
AU2017342086A1 (en) Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine
Bush Proton radiation therapy for lung cancer: is there enough evidence?
Korbelik World Journal of
JP2010535084A5 (cg-RX-API-DMAC7.html)
Marcu Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window
Jamil et al. Antibiotics: Past, present and future
Takaoka Proton Beam Therapy on Pediatric Cancer: A Review.
Alva-Sánchez et al. Preliminary Monte Carlo simulation of non-laser light sources for photodynamic therapy
RU2008137226A (ru) Способ и композиция для защиты от радиации
Trapeznikov et al. Treatment of limb osteosarcoma at the turn of the century (half century of experience in research)
Al-Yasiri et al. Proton Therapy: Technique of the Future to Treat Cancer Patients
Ballari et al. Toxicity Outcome Using Bladder-Rectum Spacer Balloon Versus Vaginal Gauze Packing in Brachytherapy in Cervical Cancer.